Blocking PDE4 with roflumilast keeps cAMP high in hindbrain neurons, extending semaglutide’s appetite‑suppressing effect.
Semaglutide’s Intracellular Dance
Semaglutide, a GLP‑1 receptor agonist, binds GLP‑1R on neurons in the area postrema and triggers a surge of cyclic adenosine monophosphate (cAMP). In mice, researchers measured this surge with fluorescence imaging, revealing a spectrum of responses: some neurons maintained elevated cAMP for hours, while others only spiked briefly before receptor internalization or degradation.
PDE4 Inhibition Skews the Response
The team selectively inhibited phosphodiesterase 4 (PDE4), the enzyme that degrades cAMP, using the drug roflumilast. This manipulation shifted the balance toward sustained cAMP elevations across a larger fraction of neurons. The effect was quantified by comparing fluorescence intensity over time, showing a statistically significant prolongation of the signal when PDE4 was blocked.
Toward Longer‑Lasting Weight Loss
Because cAMP signaling in the area postrema drives appetite suppression, sustained elevations could translate to prolonged satiety and greater weight loss. Current GLP‑1 therapies often plateau after several weeks; extending the intracellular signal might break that plateau and reduce the need for frequent injections.
Variability Among Neurons
The study highlighted that not all GLP‑1R‑expressing neurons behave identically. Some cells internalize the receptor quickly, limiting the duration of cAMP signaling. By dampening PDE4 activity, roflumilast may compensate for this variability, ensuring a more uniform response across the neuronal population.
Future Directions
The authors note that their imaging approach captures signaling over hours, not days or weeks. Future work will apply longitudinal techniques to monitor cAMP dynamics over extended periods and in larger cohorts. They also plan to test whether combining roflumilast with semaglutide improves weight‑loss outcomes in animal models.
Clinical Implications
If the rodent findings translate to humans, a co‑therapy of semaglutide and a PDE4 inhibitor could lower the required dose or injection frequency, improving adherence and reducing side‑effects. The next step will be early‑phase trials to assess safety, pharmacokinetics, and efficacy in overweight or obese patients.
The NIH study, published in Nature Metabolism (DOI: https://www.nature.com/articles/s42255-026-01534-8), opens a new avenue for enhancing GLP‑1‑based therapies by targeting intracellular signaling pathways.
Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov
Comments load interactively on the live page.